Plain-English translation of NCT07455851 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is the first study to test REGN17372 in humans. Researchers want to see if this new medication works well when given together with , a treatment that has already been used for multiple myeloma. The study will check whether the combination is safe, what side effects occur, and how well it helps control the disease compared to alone.
Multiple myeloma can come back or stop responding to standard treatments, leaving patients with few options. This medication uses a new approach to boost your immune system to fight cancer cells, and researchers hope combining it with an existing treatment will help more patients whose cancer has become difficult to treat.
You likely qualify if…
You likely don't qualify if…
You will receive the study medication through infusions at a medical center. The trial has two phases: Phase 1 focuses on safety and finding the right dose, while Phase 2 will compare how well the combination works against the single medication alone. You will have regular visits for blood tests, imaging scans, and check-ins to monitor how you're responding and watch for side effects. The study will also ask you about your quality of life and symptoms throughout your participation.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Australia